Literature DB >> 19838704

EANM procedure guidelines for brain neurotransmission SPECT/PET using dopamine D2 receptor ligands, version 2.

Koen Van Laere1, Andrea Varrone, Jan Booij, Thierry Vander Borght, Flavio Nobili, Ozlem L Kapucu, Zuzana Walker, Kjell Någren, Klaus Tatsch, Jacques Darcourt.   

Abstract

The guidelines summarize the current views of the European Association of Nuclear Medicine Neuroimaging Committee (ENC). The aims of the guidelines are to assist nuclear medicine practitioners in making recommendations, performing, interpreting and reporting the results of clinical dopamine D2 receptor SPECT or PET studies, and to achieve a high quality standard of dopamine D2 receptor imaging, which will increase the impact of this technique in neurological practice.The present document is an update of the first guidelines for SPECT using D2 receptor ligands labelled with (123)I [1] and was guided by the views of the Society of Nuclear Medicine Brain Imaging Council [2], and the individual experience of experts in European countries. The guidelines intend to present information specifically adapted to European practice. The information provided should be taken in the context of local conditions and regulations.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 19838704     DOI: 10.1007/s00259-009-1265-z

Source DB:  PubMed          Journal:  Eur J Nucl Med Mol Imaging        ISSN: 1619-7070            Impact factor:   9.236


  37 in total

1.  European Association of Nuclear Medicine procedure guidelines for brain neurotransmission SPET using (123)I-labelled dopamine D(2) transporter ligands.

Authors:  K Tatsch; S Asenbaum; P Bartenstein; A Catafau; C Halldin; L S Pilowsky; A Pupi
Journal:  Eur J Nucl Med Mol Imaging       Date:  2002-10       Impact factor: 9.236

Review 2.  PET tracers for imaging of the dopaminergic system.

Authors:  Philip H Elsinga; Kentaro Hatano; Kiichi Ishiwata
Journal:  Curr Med Chem       Date:  2006       Impact factor: 4.530

3.  Ethical clinical practice of functional brain imaging. Society of Nuclear Medicine Brain Imaging Council.

Authors: 
Journal:  J Nucl Med       Date:  1996-07       Impact factor: 10.057

4.  Biodistribution and radiation dosimetry of the dopamine D2 ligand 11C-raclopride determined from human whole-body PET.

Authors:  Mark Slifstein; Dah-Ren Hwang; Diana Martinez; Jesper Ekelund; Yiyun Huang; Elizabeth Hackett; Anissa Abi-Dargham; Marc Laruelle
Journal:  J Nucl Med       Date:  2006-02       Impact factor: 10.057

5.  Complementary PET studies of striatal neuronal function in the differential diagnosis between multiple system atrophy and Parkinson's disease.

Authors:  A Antonini; K L Leenders; P Vontobel; R P Maguire; J Missimer; M Psylla; I Günther
Journal:  Brain       Date:  1997-12       Impact factor: 13.501

6.  IBZM tool: a fully automated expert system for the evaluation of IBZM SPECT studies.

Authors:  Ralph Buchert; Georg Berding; Florian Wilke; Brigitte Martin; Daniel von Borczyskowski; Janos Mester; Winfried Brenner; Malte Clausen
Journal:  Eur J Nucl Med Mol Imaging       Date:  2006-04-14       Impact factor: 9.236

7.  Differentiating multiple system atrophy from Parkinson's disease: contribution of striatal and midbrain MRI volumetry and multi-tracer PET imaging.

Authors:  M Ghaemi; R Hilker; J Rudolf; J Sobesky; W-D Heiss
Journal:  J Neurol Neurosurg Psychiatry       Date:  2002-11       Impact factor: 10.154

8.  Optimized, automated striatal uptake analysis applied to SPECT brain scans of Parkinson's disease patients.

Authors:  I George Zubal; Michele Early; Olive Yuan; Danna Jennings; Kenneth Marek; John P Seibyl
Journal:  J Nucl Med       Date:  2007-05-15       Impact factor: 10.057

Review 9.  SPECT imaging of the dopaminergic system in (premotor) Parkinson's disease.

Authors:  Jan Booij; Remco J J Knol
Journal:  Parkinsonism Relat Disord       Date:  2007       Impact factor: 4.891

10.  The basal ganglia matching tools package for striatal uptake semi-quantification: description and validation.

Authors:  Piero Calvini; Guido Rodriguez; Fabrizio Inguglia; Alessandro Mignone; Ugo Paolo Guerra; Flavio Nobili
Journal:  Eur J Nucl Med Mol Imaging       Date:  2007-02-08       Impact factor: 10.057

View more
  13 in total

Review 1.  SPECT imaging evaluation in movement disorders: far beyond visual assessment.

Authors:  Kosmas Badiavas; Elisavet Molyvda; Ioannis Iakovou; Magdalini Tsolaki; Kyriakos Psarrakos; Nikolaos Karatzas
Journal:  Eur J Nucl Med Mol Imaging       Date:  2010-12-02       Impact factor: 9.236

2.  Calibration of gamma camera systems for a multicentre European ¹²³I-FP-CIT SPECT normal database.

Authors:  Livia Tossici-Bolt; John C Dickson; Terez Sera; Robin de Nijs; Maria Claudia Bagnara; Catherine Jonsson; Egon Scheepers; Felicia Zito; Anita Seese; Pierre Malick Koulibaly; Ozlem L Kapucu; Michel Koole; Maria Raith; Jean George; Markus Nowak Lonsdale; Wolfgang Münzing; Klaus Tatsch; Andrea Varrone
Journal:  Eur J Nucl Med Mol Imaging       Date:  2011-04-06       Impact factor: 9.236

3.  Appropriate use criteria for amyloid PET imaging cannot replace guidelines: on behalf of the European Association of Nuclear Medicine.

Authors:  Jan Booij; Javier Arbizu; Jacques Darcourt; Swen Hesse; Flavio Nobili; Pierre Payoux; Sabina Pappatà; Klaus Tatsch; Zuzana Walker; Marco Pagani
Journal:  Eur J Nucl Med Mol Imaging       Date:  2013-07       Impact factor: 9.236

4.  ¹²⁴I-Epidepride: a PET radiotracer for extended imaging of dopamine D2/D3 receptors.

Authors:  Suresh Pandey; Archana Venugopal; Ritu Kant; Robert Coleman; Jogeshwar Mukherjee
Journal:  Nucl Med Biol       Date:  2014-01-31       Impact factor: 2.408

5.  Comparison of two neural network classifiers in the differential diagnosis of essential tremor and Parkinson's disease by (123)I-FP-CIT brain SPECT.

Authors:  Barbara Palumbo; Mario Luca Fravolini; Susanna Nuvoli; Angela Spanu; Kai Stephan Paulus; Orazio Schillaci; Giuseppe Madeddu
Journal:  Eur J Nucl Med Mol Imaging       Date:  2010-06-23       Impact factor: 9.236

Review 6.  Recent Advancement and Clinical Implications of 18FDG-PET in Parkinson's Disease, Atypical Parkinsonisms, and Other Movement Disorders.

Authors:  Cecilia Peralta; Federico Biafore; Tamara Soto Depetris; Maria Bastianello
Journal:  Curr Neurol Neurosci Rep       Date:  2019-06-29       Impact factor: 5.081

Review 7.  Dopamine transporter SPECT imaging in Parkinson’s disease and parkinsonian disorders

Authors:  Ümit Özgür Akdemir; Ayşe Bora Tokçaer; Lütfiye Özlem Atay
Journal:  Turk J Med Sci       Date:  2021-04-30       Impact factor: 0.973

Review 8.  Single Photon Emission Computed Tomography/Positron Emission Tomography Molecular Imaging for Parkinsonism: A Fast-Developing Field.

Authors:  Antoine Verger; Stephan Grimaldi; Maria-Joao Ribeiro; Solène Frismand; Eric Guedj
Journal:  Ann Neurol       Date:  2021-08-27       Impact factor: 11.274

9.  Dopamine transporter single-photon emission computerized tomography supports diagnosis of akinetic crisis of parkinsonism and of neuroleptic malignant syndrome.

Authors:  G Martino; M Capasso; M Nasuti; L Bonanni; M Onofrj; A Thomas
Journal:  Medicine (Baltimore)       Date:  2015-04       Impact factor: 1.889

10.  Nuclear Medicine Imaging in Pediatric Neurology.

Authors:  Ümit Özgür Akdemir; Lütfiye Özlem Atay Kapucu
Journal:  Mol Imaging Radionucl Ther       Date:  2016-02-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.